Top entities: Paragon Therapeutics, United States — Food and Drug Administration, Linda Marban, United States, European Union — European Medicines Agency.

What category does this event fall under?

Regulatory — classified as regulatory decision.

What is the sentiment of coverage?

Aggregate sentiment score: -30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 30, 2026. Coverage continues to evolve.

Regulatory regulatory decision

FDA panel votes against Deramiocel

Q: When did this event occur?

First reported Jul 27, 2026; last updated Jul 30, 2026.

Q: What is the market impact?

General. The negative advisory committee vote may reduce the likelihood of FDA approval for Deramiocel, potentially impacting Capricor's stock price and future revenue prospects.

Analysis based on 11 articles · First reported Jul 27, 2026 · Last updated Jul 30, 2026

Sentiment

-30

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The negative advisory committee vote may reduce the likelihood of FDA approval for Deramiocel, potentially impacting Capricor's stock price and future revenue prospects. However, the non-binding nature and supportive feedback on skeletal muscle leave some hope for approval.

Biotechnology Pharmaceuticals

Event Summary

On July 30, 2026, the U.S. United States — Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 that available evidence did not support the effectiveness of Paragon Therapeutics' Deramiocel for treating cardiomyopathy in Duchenne muscular dystrophy (DMD) patients. The vote is non-binding. The committee's feedback on upper limb function was directionally supportive. Capricor remains committed to working with the FDA ahead of the August 22, 2026 PDUFA date.

Key Actions

100 United States — Food and Drug Administration denied Biologics License Application Paragon Therapeutics

Entities Involved

priv

Paragon Therapeutics

Capricor is the sponsor of Deramiocel; the negative vote could delay or prevent approval, affecting its lead product candidate and financial outlook.

Importance 100.0 Sentiment -40.0

govactor

United States — Food and Drug Administration

The FDA's advisory committee provided a non-binding negative vote; the FDA will make the final decision by the PDUFA date.

Importance 80.0 Sentiment 0.0

per

Linda Marban

As CEO, she expressed continued commitment to Deramiocel and confidence in the data despite the vote.

Importance 50.0 Sentiment -20.0

cnt

United States

The U.S. is the regulatory jurisdiction for the FDA decision; DMD affects approximately 15,000 individuals in the U.S.

Importance 30.0 Sentiment 0.0

govactor

European Union — European Medicines Agency

The EMA has granted Orphan Drug Designation for Deramiocel; the vote does not directly affect European regulatory status.

Importance 20.0 Sentiment 0.0

stock

Nippon Shinyaku

Mentioned in forward-looking statements regarding litigation; not directly involved in the advisory committee meeting.

Importance 10.0 Sentiment 0.0

subs

Nippon Shinyaku — NS Pharma

Mentioned in forward-looking statements regarding litigation; not directly involved in the advisory committee meeting.

Importance 10.0 Sentiment 0.0

Relationships

Paragon Therapeutics related ↔ United States — Food and Drug Administration

United States — Food and Drug Administration related ↔ United States

United States — Food and Drug Administration related ↔ European Union — European Medicines Agency

United States related ↔ European Union — European Medicines Agency

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard